MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers

Retrospective Comparison of Chemoradiotherapy Followed by Adjuvant Chemotherapy, With or Without Prior Gliadel Implantation (Carmustine) After Initial Surgery in Patients With Newly Diagnosed High-Grade Gliomas

(2011) Georges Noël et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Targeting O 6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy

(2010) Bernd Kaina et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience

(2010) Hans Christoph Bock et al.   NEUROSURGICAL REVIEW

Risk Management in the Treatment of Malignant Gliomas with BCNU Wafer Implants

(2010) A. Giese et al.   Central European neurosurgery

Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation

(2009) Philippe Metellus et al.   CANCER

Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients

(2009) J. Felsberg et al.   CLINICAL CANCER RESEARCH

Evidence-based adjuvant therapy for gliomas: Current concepts and newer developments

(2009) ST Chao et al.   INDIAN JOURNAL OF CANCER

Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide

(2009) Martin Glas et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience

(2008) Michael Sabel et al.   CURRENT MEDICAL RESEARCH AND OPINION

Phase I analysis of BCNU-impregnated biodegradable polymer wafers followed by systemic interferon alfa-2b in adults with recurrent glioblastoma multiforme

(2008) Jeffrey J. Olson et al.   JOURNAL OF NEURO-ONCOLOGY

Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme

(2008) Matthew J. McGirt et al.   JOURNAL OF NEUROSURGERY

Carmustine-Resistant Cancer Cells Are Sensitized to Temozolomide As A Result of Enhanced Mismatch Repair during the Development of Carmustine Resistance

(2008) T. Yamauchi et al.   MOLECULAR PHARMACOLOGY